Simple Summary The aims of this study are:(1) to analyze the risk of vein thrombosis and
pulmonary embolism in patients affected by pneumonia due to Covid-19;(2) to evaluate …

Objective To evaluate the rate of thrombosis, bleeding and mortality comparing
anticoagulant doses in critically ill COVID-19 patients. Design Retrospective observational …

Background Thromboprophylaxis of COVID-19 patients is a highly debated issue. We aimed
to compare the occurrence of thrombotic/ischemic events in COVID-19 patients with acute …

Many aspects of care such as management of hypercoagulable state in COVID-19 patients,
especially those admitted to intensive care units is challenging in the rapidly evolving …

Background Because of the high risk of thrombotic complications (TCs) during SARS-CoV-2
infection, several scientific societies have proposed to increase the dose of preventive …

Coagulopathy in COVID-19 is a burning issue and strategies to prevent thromboembolic
events are debated and highly heterogeneous. The objective was to determine incidence …

Patients with COVID-19 may complicate their evolution with thromboembolic events.
Incidence of thromboembolic complications are high and also, patients with the critically-ill …

Background Coagulopathy is a common abnormality in patients with COVID‐19. However,
the exact incidence of venous thromboembolic event is unknown in anticoagulated, severe …

Despite thromboprophylaxis, patients with coronavirus disease 2019 (COVID‐19) exhibit
hypercoagulability and higher venous thromboembolic risk, although its real incidence is still …

Introduction The risk of mortality in patients with COVID-19 was found to be significantly
higher in patients who experienced thromboembolic events. Thus, several guidelines …